Biomolecular Life Holdings, Inc.

As of September 30, 2015, Biomolecular Life Holdings, Inc. carries a market capitalization of 99.57B, placing it among publicly traded companies globally. Its enterprise value stands at 99.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of September 30, 2015, Biomolecular Life Holdings, Inc. has 101.50M shares outstanding.

These figures are as of September 30, 2015.

As of September 30, 2015, Biomolecular Life Holdings, Inc. maintains a current ratio of 0.01, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -77.90, indicating conservative leverage, while an interest coverage ratio of -1.32 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended September 30, 2015. Return on assets (ROA) is negative at -381.35, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 1.00, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Biomolecular Life Holdings, Inc.'s stock has declined approximately 11.00% over the past 52 weeks. The 50-day moving average sits at 0.55, while the 200-day moving average is 1.07.

Over the twelve months ended September 30, 2015, Biomolecular Life Holdings, Inc. generated - - in revenue and converted that into -4.30M in net income, yielding earnings per share of -0.07. EBITDA reached -2.73M, while operating income came in at -2.73M.

As of September 30, 2015, Biomolecular Life Holdings, Inc. holds 22,919.00 in cash and equivalents against 3.38M in total debt, resulting in a net debt position of 3.36M. Total book value stands at -4.98M, with working capital of -5.42M providing operational flexibility.

Biomolecular Life Holdings, Inc. produced -858,336.00 in operating cash flow over the twelve months ended September 30, 2015.

Biomolecular Life Holdings, Inc.'s most recent stock split took place on April 16, 2026.

As of September 30, 2015, Biomolecular Life Holdings, Inc. has an Altman Z-Score of 6,740.72, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.